<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03607825</url>
  </required_header>
  <id_info>
    <org_study_id>R1.0 11July18</org_study_id>
    <nct_id>NCT03607825</nct_id>
  </id_info>
  <brief_title>FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR Extension</brief_title>
  <acronym>PILLAR-XT</acronym>
  <official_title>ExtracorPoreal FILtration of Subarachnoid Hemorrhage Via SpinaL CAtheteR EXTension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minnetronix</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minnetronix</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to further demonstrate safety and characterize effectiveness
      of the Neurapheresis™ System (extracorporeal system and catheter) to remove red blood cells
      (RBCs) and lysed blood by-products from hemorrhagic cerebrospinal fluid (CSF) following
      aneurysmal subarachnoid hemorrhage (aSAH).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The PILLAR-XT study is designed to further confirm safety and characterize efficacy of
      Neurapheresis therapy. The study works in tandem with the current SOC treatments for SAH and
      does not detract from the established care pathways, or deny enrolled subjects proven
      therapies. The PILLAR-XT study utilizes the established skill sets of chosen Investigators
      who are already trained in the treatment and care of SAH patients and insertion/management of
      lumbar drains.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 25, 2018</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Change in Cisternal Blood</measure>
    <time_frame>Immediately post treatment</time_frame>
    <description>Documented by CT</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Red Blood Cells</measure>
    <time_frame>Immediately post treatment</time_frame>
    <description>CSF analysis of RBCs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Total Protein</measure>
    <time_frame>Immediately post treatment</time_frame>
    <description>CSF analysis of Total Protein</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Subarachnoid Hemorrhage</condition>
  <arm_group>
    <arm_group_label>Neurapheresis System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CSF filtration</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Neurapheresis System</intervention_name>
    <description>CSF filtration system and lumbar catheter</description>
    <arm_group_label>Neurapheresis System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Modified Fisher Grade 2, 3 or 4

          -  Hunt &amp; Hess I-IV

          -  First aneurysmal SAH

          -  Patient is ≤ 48 hours post bleeding event

          -  World Federation of Neurosurgeons (WFNS) Grades I-IV

        Exclusion Criteria:

          -  Pregnancy

          -  Patients with a SAH due to mycotic aneurysm or AV malformation

          -  Patients who present with an acute MI or unstable angina

          -  Imaging demonstrates supratentorial mass lesions greater than 50 cc

          -  Imaging demonstrates more than 5 mm of mid-line-shift associated with infarction and
             or edema

          -  Effacement of the basilar cisterns

          -  Vasospasm on admission as defined by angiographic evidence

          -  Patients with a coagulopathy that cannot be reversed

          -  Thrombocytopenia def. platelet count &lt; 100,000

          -  Patients on low molecular weight heparin such as Lovenox

          -  Non-communicating Obstructive hydrocephalus

          -  Existing hardware that prevents accurate CT imaging

          -  Pre-existing Lumbar Drain

          -  Local skin infections or eruptions over the puncture site

          -  Signs of CNS systemic infection, sepsis or pneumonia
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Julie Messer</last_name>
    <phone>651-917-4060</phone>
    <email>jmesser@minnetronix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Memorial Hermann</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Messer</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 23, 2018</study_first_submitted>
  <study_first_submitted_qc>July 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2018</study_first_posted>
  <last_update_submitted>February 18, 2020</last_update_submitted>
  <last_update_submitted_qc>February 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aneurysmal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

